AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01409694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Study NCT02995928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Description: Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
Study NCT02995928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
Study NCT02995928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
Study NCT02076113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral (Front) decompression with Fusion
Description: Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
Study NCT02076113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal (Back) Decompression with Fusion
Description: Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
Study NCT02076113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal (back) Laminoplasty
Description: Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
Study NCT01513759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator
Description: Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
Study NCT01409694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Study NCT01409694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
Study NCT01513759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKOS EkoSonic Endovascular System
Description: 24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
Study NCT03237481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
Study NCT01409694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
Study NCT01266239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kissing balloon inflation
Description: Kissing balloon inflation following the MV stenting
Study NCT01266239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES vs. SES
Description: Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
Study NCT03037944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin
Description: (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
Study NCT03037944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metraplant-E
Description: Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013
Study NCT03981003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: 2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
Study NCT03952884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
Study NCT03952884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
Study NCT03952884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Resistance Exercise
Description: Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
Study NCT03952884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Resistance Exercise
Description: Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
Study NCT03952884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
Study NCT03952884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dileucine
Description: Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
Study NCT03775005 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03775005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 1800 cGy in 4 fractions administered twice a day
Study NCT03955484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Glycosaminoglycan
Description: Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
Study NCT02972697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-acetate ligand
Study NCT02972697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG ligand
Study NCT02966080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HEP-IV
Study NCT03237481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine, 75 mg by injection
Study NCT03237481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline placebo by instillation
Study NCT03237481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer-lock applicator
Description: Applicator for instillation
Study NCT02262429 — intervention group
Intervention type: OTHER
Intervention: ONS QIP
Description: Rapid comprehensive ONS, dietary consult, follow up phone calls
Study NCT02262429 — intervention group
Intervention type: OTHER
Intervention: ONS Standard Feeding
Description: Standard of care
Study NCT05658926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Patients will learn how to use diaphragmatic breathing with mindfulness
Study NCT05658926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patients will be provided with education regarding the Gate Control Theory of Pain.
Study NCT00506935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVG
Description: 5 grams GVG
Study NCT00506935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00636454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) for chronic pain
Description: Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
Study NCT00636454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the care usually given to patients with knee or hip OA.
Study NCT04279925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORIF (Open reduction internal fixation): locally-made miniplate and screw
Description: Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
Study NCT04279925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF: Imported miniplate and screw
Description: Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
Study NCT03109834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement (MR)
Description: MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)
Study NCT03109834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (C)
Description: During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)
Study NCT03109834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Verum
Description: Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)
Study NCT03109834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)
Study NCT02815111 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Receive an analgesic regimen that involves Ketamine infusions
Study NCT02815111 — intervention group
Intervention type: DRUG
Intervention: Lidocaine
Description: Receive an analgesic regimen that involves Lidocaine infusions
Study NCT02815111 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
Study NCT02815111 — intervention group
Intervention type: DRUG
Intervention: Neurontin
Description: May be given Neurontin by mouth as an approved medication for pain control
Study NCT03267238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
Study NCT05289102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two postpartum visits.
Description: Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
Study NCT05289102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One postpartum visit.
Description: Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
Study NCT01709058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular/paravertebral injections of Oxygen-Ozone
Description: Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL
Study NCT01709058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simulated intramuscular/paravertebral injections
Description: The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
Study NCT04273958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality helmet
Description: During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
Study NCT04273958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer screen
Description: During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
Study NCT02723617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MED 0.5
Description: Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
Study NCT02723617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MED 2.5
Description: Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
Study NCT02723617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MED 5.5
Description: Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
Study NCT02723617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AAD 2.5
Description: Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
Study NCT01911364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB
Description: Superiority over Tiotropium
Study NCT01911364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Superiority of CHF5993 over Tiotropium
Study NCT01911364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP/FF + Tiotropium
Description: non inferiority vs CHF5993
Study NCT02251535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE® Knee System
Study NCT02251535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC® SIGMA® Knee System
Study NCT03237481 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Luer-lock applicator
Description: Applicator for instillation
Study NCT03237481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product
Study NCT04390100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid (Gengiegel 0.2% oral gel )
Description: coverage of the free gingival graft area in the palate
Study NCT04390100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: coverage of the free gingival graft area in the palate
Study NCT04390100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel foam
Description: coverage of the free gingival graft area in the palate
Study NCT03025165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Adherence Clubs
Description: Provision of ART care in the community to a club of 20-25 HIV+ patients
Study NCT03025165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based ART Delivery
Description: Provision of ART care to an individual at their home
Study NCT03025165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
Study NCT00889421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: oral dose of 30 mg BID for 6 months
Study NCT03136601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTNS maintenance
Description: The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
Study NCT03136601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTNS maintenance
Description: The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
Study NCT03314987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnosine
Description: a naturally occurring di-peptide
Study NCT03314987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an identically appearing supplement
Study NCT01721200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Support Tool
Description: Educational decision support tool for patients with rheumatoid arthritis
Study NCT01958918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injection
Study NCT01958918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg intravitreal injection
Study NCT01319006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out